Published in Can J Gastroenterol on March 01, 2012
Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med (2013) 1.01
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One (2013) 0.91
Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol (2014) 0.79
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology (2010) 1.47
Chronic hepatitis B infection in Canada. Can J Infect Dis (2001) 0.99
Management of hepatitis B: a longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines. Can J Gastroenterol (2010) 0.89
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J (2005) 1.99
Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (2004) 1.97
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2012) 1.71
Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS (2011) 1.55
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol (2011) 1.46
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int (2014) 1.42
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.38
HIV/AIDS in African militaries: an ecological analysis. Med Confl Surviv (2008) 1.34
Users' guides to the medical literature: how to use an article about mortality in a humanitarian emergency. Confl Health (2008) 1.28
Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol (2010) 1.27
Traditional African medicine in the treatment of HIV. Lancet Infect Dis (2005) 1.23
Adherence to antiretroviral therapy among a conflict-affected population in Northeastern Uganda: a qualitative study. AIDS (2008) 1.22
Barriers to participation in HIV drug trials: a systematic review. Lancet Infect Dis (2006) 1.17
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol (2009) 1.17
Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol (2012) 1.14
Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One (2013) 1.08
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr (2010) 1.05
The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol (2004) 1.04
Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. BMC Med Res Methodol (2013) 1.01
Pediatric HIV therapy in armed conflict. AIDS (2008) 0.99
Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS (2014) 0.98
Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav (2011) 0.97
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health (2014) 0.96
Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. Can J Public Health (2004) 0.96
The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95
Ensuring sustainable antiretroviral provision during economic crises. AIDS (2010) 0.94
Orphanhood predicts delayed access to care in Ugandan children. Pediatr Infect Dis J (2009) 0.94
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol (2011) 0.94
Simple, effective interventions are key to improving adherence in marginalized populations. Clin Infect Dis (2007) 0.93
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob (2009) 0.93
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther (2007) 0.93
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92
Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther (2014) 0.92
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infect Dis (2010) 0.91
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother (2013) 0.89
A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D (2008) 0.88
Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis (2013) 0.86
Clinical significance of hepatitis B core antibody positivity in HCV-infected and HCV/HIV coinfected individuals. Clin Infect Dis (2004) 0.85
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr (2011) 0.85
Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Eur J Gastroenterol Hepatol (2009) 0.85
Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001-2011. J Acquir Immune Defic Syndr (2015) 0.84
Liver toxicity resulting from syphilis and Jarish-Herxheimer reaction in cases of coinfection with HIV and hepatitis C virus. Clin Infect Dis (2005) 0.83
Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. Antivir Ther (2012) 0.83
Long-term health care interruptions among HIV-positive patients in Uganda. J Acquir Immune Defic Syndr (2013) 0.83
Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS (2014) 0.83
The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. Can J Gastroenterol Hepatol (2014) 0.82
Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS (2012) 0.81
Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Qual Life Res (2012) 0.81
Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C. Can J Gastroenterol (2006) 0.81
The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS One (2011) 0.81
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials (2008) 0.80
Gender disparities in HIV risk behavior and access to health care in St. Petersburg, Russia. AIDS Patient Care STDS (2013) 0.80
Randomized trials stopped early for harm in HIV/AIDS: a systematic survey. HIV Clin Trials (2006) 0.80
Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. AIDS (2013) 0.79
Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada. J Int Assoc Provid AIDS Care (2013) 0.79
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. Transplantation (2016) 0.79
Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leuk Lymphoma (2013) 0.79
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol (2014) 0.78
The influence of race and language on chronic hepatitis C virus infection management. Eur J Gastroenterol Hepatol (2009) 0.78
HIV knowledge among Canadian-born and sub-Saharan African-born patients living with HIV. J Immigr Minor Health (2012) 0.78
Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care (2013) 0.78
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. J Clin Pharmacol (2015) 0.77
Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes. Can J Gastroenterol Hepatol (2014) 0.77
Validation of the Episodic Disability Framework with adults living with HIV. Disabil Rehabil (2013) 0.77
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients. AIDS (2016) 0.76
Time-dependent bias in hepatitis C classification. Epidemiology (2015) 0.76
Relationships between dimensions of disability experienced by adults living with HIV: a structural equation model analysis. AIDS Behav (2014) 0.76
Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials (2015) 0.76
Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. Can J Gastroenterol Hepatol (2013) 0.75
Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels. Can J Gastroenterol Hepatol (2015) 0.75
Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis. Can J Gastroenterol (2013) 0.75
A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 0.75
Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. Hum Vaccin Immunother (2013) 0.75
HIV-HCV Co-infection therapeutic outcomes have not improved over time. HIV Clin Trials (2009) 0.75
Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. Can J Public Health (2017) 0.75
Gastrointestinal Symptom Distress is Associated With Worse Mental and Physical Health-Related Quality of Life. J Acquir Immune Defic Syndr (2017) 0.75
Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort. Clin Infect Dis (2013) 0.75
The use of multistate models to examine associations of stress and adherence with transitions among HIV care states observed in a clinical HIV cohort. J Acquir Immune Defic Syndr (2017) 0.75